CEO Mehta to hold a Key Opinion Leader Day focused on its lead immuno-oncology program BXCL701 on February 21 at 1 pm. Webcast Link
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BTAI:
- BioXcel Therapeutics to hold Key Opinion Leader Day
- BioXcel Therapeutics Announces Positive Full Data from Phase 2 Trial of BXCL701 in Rare, Aggressive Form of Prostate Cancer; to be Presented at 2023 ASCO Genitourinary Cancers Symposium
- BioXcel announces seven patients achieve composite response in BXCL701 trial
- BioXcel Therapeutics to host BXCL701 KOL Day
- BioXcel Therapeutics to Host BXCL701 Key Opinion Leader Day to Highlight Company’s Investigational, Oral Innate Immune Activator for Rare Form of Prostate Cancer